All News

10 December 2007

Genitope Corporation Presents New Data On Its Therapeutic Monoclonal Antibodies To Potentially Treat B-Cell MalignanciesAntibodies

9 December 2007

ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE9633Antibodies

8 December 2007

ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting with Targeted Anticancer Compounds IMGN901 (HuN901-DM1) and AVE1642Antibodies

7 December 2007

Genmab’s HuMax-CD38 Enters Phase I/II Clinical Trial For Multiple MyelomaAntibodies

7 December 2007

Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin’s LymphomaAntibodies

6 December 2007

Raven biotechnologies, Inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven AntibodiesAntibodies

5 December 2007

Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal CancerAntibodies

5 December 2007

Genentech Provides Update From Avastin FDA Advisory MeetingAntibodies

5 December 2007

Panacea Pharmaceuticals Announces Selection of PAN-622 – A Fully Human Sequence Monoclonal Antibody Against HAAH – As Its Lead Cancer Therapeutic ProductAntibodies

5 December 2007

BioInvent Designates Drug Candidate, BI-505, for the Treatment of CancerAntibodies

5 December 2007

Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary EndpointAntibodies

4 December 2007

Centocor and Janssen-Cilag Submit Appplications Requesting Approval of Ustekinumab in the U.S. and Europe For Treatment of Moderate to Severe Plaque PsoriasisAntibodies

4 December 2007

Arana Announces Phase II Trials For Lead Compound ART621Antibodies

4 December 2007

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH PatientsAntibodies

4 December 2007

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342Antibodies

4 December 2007

Eisai and BioArctic Neuroscience Enter Exclusive Licensing AgreementAntibodies

3 December 2007

“Actemra(R),” a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in EuropeAntibodies

2 December 2007

Novartis further strengthens biologics capabilities in expansion of MorphoSys collaborationAntibodies

29 November 2007

Regeneron Initiates Major Global Collaboration with Sanofi-aventis to Develop and Commercialize Fully-Human Therapeutic AntibodiesAntibodies

29 November 2007

New Data Highlight That Treatment With Erbitux Allows More Resections of Preteated Patients With Metastatic Colorectal CancerAntibodies

28 November 2007

MediGene and Celltrion Announce Co-development of Anti-L1 Monoclonal Antibody Therapeutic for Treating CancerAntibodies

26 November 2007

MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid ArthritisAntibodies

21 November 2007

Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid ArthritisAntibodies

21 November 2007

Kyto Biopharma Inc. Confirms Definitive Isolation of the Human Vitamin B12 Receptor (TCblR)Antibodies

20 November 2007

Biogen Idec and Neurimmune Therapeutics Announce Alliance to Develop Treatments for Alzheimer’s DiseaseAntibodies

20 November 2007

Genmab and Glaxosmithkline Initiate Ofatumumab Rheumatoid Arthritis Phase III ProgramAntibodies

19 November 2007

Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of AdenocarcinomasAntibodies

19 November 2007

Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain CancerAntibodies

16 November 2007

Abbott’s HUMIRA(R) Receives Positive Opinion from EMEA for Treatment of Moderate to Severe Plaque PsoriasisAntibodies

16 November 2007

UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn’s DiseaseAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals